Free Trial

Lyra Therapeutics (LYRA) SEC Filings & 10K Form

Lyra Therapeutics logo
$0.18 +0.01 (+5.88%)
(As of 12/20/2024 05:31 PM ET)

Recent Lyra Therapeutics SEC Filings

DateFilerForm TypeView
12/16/2024
8:02 PM
Lyra Therapeutics (Subject)
PERCEPTIVE ADVISORS LLC (Filed by)
Form SC 13D/A
12/13/2024
4:06 PM
Lyra Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/11/2024
5:39 PM
Lyra Therapeutics (Issuer)
Waksal Harlan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2024
5:54 PM
Lyra Therapeutics (Issuer)
Palasis Maria (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/14/2024
6:48 PM
Lyra Therapeutics (Subject)
Point72 Asset Management, L.P. (Filed by)
Form SC 13G/A
11/14/2024
4:48 PM
Lyra Therapeutics (Subject)
Samsara BioCapital, L.P. (Filed by)
Form SC 13G/A
11/14/2024
4:49 PM
Lyra Therapeutics (Subject)
Venrock Healthcare Capital Partners II, L.P. (Filed by)
Form SC 13G/A
11/14/2024
3:53 PM
Lyra Therapeutics (Subject)
Nantahala Capital Management, LLC (Filed by)
Form SCHEDULE 13G/A
08/15/2024
5:31 PM
Lyra Therapeutics (Subject)
PERCEPTIVE ADVISORS LLC (Filed by)
Form SC 13D/A
07/23/2024
3:05 PM
Lyra Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/07/2024
3:15 PM
Lyra Therapeutics (Filer)
Form 8-K/A
05/21/2024
8:15 AM
Lyra Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/30/2024
3:15 PM
Lyra Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/29/2024
3:36 PM
Lyra Therapeutics (Filer)
Form DEFA14A
04/19/2024
3:17 PM
Lyra Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/19/2024
3:20 PM
Lyra Therapeutics (Filer)
Form PRE 14A
04/01/2024
11:15 PM
Lyra Therapeutics (Filer)
Form EFFECT
03/22/2024
6:38 AM
Lyra Therapeutics (Filer)
Form S-3
Registration statement under Securities Act of 1933  
03/22/2024
6:41 AM
Lyra Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/22/2024
5:58 AM
Lyra Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/20/2024
6:20 PM
Lyra Therapeutics (Issuer)
Palasis Maria (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/20/2024
6:21 PM
Lyra Therapeutics (Issuer)
Waksal Harlan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/15/2024
8:18 AM
Lyra Therapeutics (Subject)
PURA VIDA INVESTMENTS, LLC (Filed by)
Form SC 13G/A
02/14/2024
7:35 PM
Lyra Therapeutics (Subject)
Venrock Healthcare Capital Partners II, L.P. (Filed by)
Form SC 13G/A
02/14/2024
5:18 PM
CITADEL ADVISORS LLC (Filed by)
Lyra Therapeutics (Subject)
Form SC 13G/A
01/08/2024
5:13 AM
Lyra Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/28/2023
5:40 AM
Lyra Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:LYRA) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners